RecruitingNot Applicable

Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment

United States150 participantsStarted 2023-01-15

Plain-language summary

In this study, the investigators aim to compare a mobile health platform, known as a 'chatbot,' that leverages artificial intelligence and natural language processing to scale communication, to 'usual care' that patients would receive. This comparison will enable the investigators to determine if the chatbot system can improve rates of recommendation for genetic testing among patients at elevated risk of harboring a familial cancer syndrome in an all-Medicaid gynecology clinic. Furthermore, the investigators aim to evaluate facilitators of inequity in regard to patient access to and utilization of genetic testing services.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 8 years of age or older. * Scheduled for a New Patient appointment in the gynecology clinic. Speaks and reads in English. * Access to a telephone with texting capacity. * Has not had prior genetic testing for hereditary cancer syndromes. Exclusion Criteria: * Under 18 years of age * Has had previous genetic testing for hereditary cancer syndromes * Does not read/speak in English * Does not have access to a phone with texting capabilities

What they're measuring

Proportion recommended genetic testing

Timeframe: 2 years

Trial details

NCT IDNCT05562778

SponsorWeill Medical College of Cornell University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

Contact for this trial

Melissa K Frey, MD, MS

212-746-3049 mkf2002@med.cornell.edu

View on ClinicalTrials.gov More Gynecologic Cancer trials